致奶牛乳房炎金葡菌亚单位疫苗与原核表达牛IL-6的佐剂效果研究
摘要
奶牛乳房炎是影响奶牛养殖业最重要的疾病之一,可以引起产奶量及乳品质量下降,花费巨额的治疗费用而给奶牛养殖业带来巨大的经济损失。奶牛乳房炎是多病因疾病,因为乳房炎发生过程中有大量的微生物参与,使用疫苗预防也就成为乳房炎防控的一个重要策略。
金葡菌是引起奶牛乳房炎与乳品微生物污染的主要病原菌之一,发展有效的金葡菌疫苗是控制临床型乳房炎的关键,已经有疫苗得到了推广应用。随着生物技术的发展,新型疫苗不断涌现,科研人员也用新技术去研究金葡菌疫苗。随着对金葡菌侵染过程的了解,人们认识到金葡菌黏附到细胞或细胞外基质上是感染的关键步骤,用特异性抗体阻断金葡菌的黏附过程可能为金葡菌乳房炎的防治提供一个有效的策略,参与细菌黏附过程的分子就成为潜在的抗原分子。已知参与金葡菌黏附的主要分子有纤维结合素结合蛋白(FnBP)、凝集因子A (ClfA)、凝集因子B(ClfB)、胶原连接蛋白(Can)等。
本研究采用原核表达的FnBP和ClfA蛋白,纯化后制备亚单位疫苗,免疫小鼠进行疫苗评价。因为金葡菌是典型的胞外寄生菌,体液免疫对预防金葡菌感染起重要作用,IL-6的作用之一就是促进抗体的产生,本研究克隆表达出奶牛白细胞介素6(IL-6)作为亚单位疫苗的佐剂。用小鼠进行乳房炎疫苗效果评价,要先建立小鼠乳房炎模型,取泌乳8-10天的小鼠,第四对乳腺内注射不同剂量的金葡菌或PBS,2h后母子合笼,24h后处死母鼠,取乳腺进行一侧甲醛固定进行病理检测,另外一侧研磨检测组织中金葡菌的数量和TNF-α的浓度。用纯化的FnBP和C1fA蛋白加入氟氏不完全佐剂制备亚单位疫苗,培养金葡菌收菌后通过反复冻融超声破碎加入氟氏不完全佐剂制备全菌疫苗,间隔14天免疫小鼠两次,一部分使怀孕,泌乳后攻菌,另一部分加强免疫时注射不同的佐剂(PHA,LPS,IL-6,IFN-γ,胸腺肽),免疫不同时间点采血分离血清,用ELISA法检测血清中抗体水平。
结果成功克隆表达了奶牛IL-6基因,并纯化出蛋白；建立了金葡菌感染小鼠乳房炎模型,确定1.0×103cfu／只金葡菌是合适的乳腺内感染剂量,和评价小鼠乳房炎的严重程度三个有效指标。免疫结果显示,亚单位疫苗和全菌疫苗都可以减轻乳腺内感染金葡菌造成的乳房炎严重程度,表现为病理变化轻,组织中金葡菌数量少,TNF-α水平低。以全菌总蛋白为抗原,用琼扩试验检测血清中的抗体,只有全菌免疫组有可见的沉淀线,以纯化的两种蛋白包板,用ELISA检测血清中的抗体显示亚单位疫苗组的抗体水平最高。而5种不同种类的佐剂对血清中抗体的水平有不同的影响,其中以胸腺肽增加血清中抗体的作用最明显。
Bovine mastitis, one of the most significant disease of dairy herds, has huge effects on farm economics due to reduction in milk production and treatment costs. It's a multiple reasons disease, thus we must Application of a variety of measures to control bovine mastitis.As there are many kinds of Microorganism have a role in the processes of mastitis, the vaccine become a important target for control bovine mastitis.
Staphylococcus aureus (S. aureus) is the main causative agent of bovine mastitis, development an efficient vaccine of S.aureus is important for control the infection,there are several vaccines used in commercially herds, but the economic benefit following such treatment has not been uniformly demonstrated. With the development of biotechnology, new type vaccine emerged one after another, researchers also used these new technology for the vaccine 'invention. Followed the knowledge improve about the S.aureus infected in mammary gland, peoples found it's the key step of S.aureus adhesion to the host celles or extracelluar matrix. The adhesion molecules yet become the potential candidate antigens. As is know about the molecules include the Fibronectin binding protein (FnBP), clumping factor A (ClfA),clumping factor B(ClfB), Collagen-binding protein Can (Can) et al.
In this study, we choose prokaryotic express proteins of FnBP and ClfA, purificated for prepared the subunit vaccine. Evaluate the effectiveness on mouse model. S. aureus is a bacteria planted out of the host celles, Humoral immune palys an important role in resistancing S. aureus infection. As well know it have an important role to enhance the IgG level. That we clones the IL-6 gene of cows and expressed in prokaryotic express system. Using the IL-6 as an adjuvant for subunit vaccine. We established a mastitis mouse model before to evaluated the vaccine, take mice at 8-10days during lactating, injection different dose S. aureus or PBS into the fourth pair mammary glands,2 hours later take mother-children co-cage,24 hours apart after injection, killed mice by cervical pull, remove one side of mammary gland fixed for histopathologic evaluations, another side pulverization to detect the bacteria amount and the tumor necrosis factor (TNF-α) concentration. Through the mouse model we gained the suitable dose of S. aureus to challenge after vaccination. Take purificated proteins add adjuvant prepared subunit vaccine, and collection S. aureus lysis using Ultrasonic, add adjuvant to prepared total bacteria vaccine. Mice were vaccinated twice 14 days apart, one group cohabit to pregnancy, after parturition give S. aureus injection to challenge evaluation, another group give different adjuvant (PHA, LPS, IL-6, IFN, thymosin) with second vaccinated, haemospasia and apart serum every week, detect the IgG level in serum used the ELISA.
Results, we got purificated bovine IL-6, through clone and prokaryotic expression, established a mastitis mouse model, gained the suitable dose of S. aureus was 1.0×103cfu per mouse.and the scientific criteria to evaluated the severity of mouse mastitis. Both of the two vaccine can significantly reduce the severity of mastitis in mouse model, with a light histopathologic changes, lower TNF-αlevel and a small amount of bacteria in mammary gland tissues.The total protein vaccine group shown a highest total IgG level, but the subunit vaccine group shown a highest anti-FnBP & ClfA antibody, every adjuvant can enhance the IgG level rising significantly, the thymosin was the best one between the five adjuvants.
金葡菌是引起奶牛乳房炎与乳品微生物污染的主要病原菌之一,发展有效的金葡菌疫苗是控制临床型乳房炎的关键,已经有疫苗得到了推广应用。随着生物技术的发展,新型疫苗不断涌现,科研人员也用新技术去研究金葡菌疫苗。随着对金葡菌侵染过程的了解,人们认识到金葡菌黏附到细胞或细胞外基质上是感染的关键步骤,用特异性抗体阻断金葡菌的黏附过程可能为金葡菌乳房炎的防治提供一个有效的策略,参与细菌黏附过程的分子就成为潜在的抗原分子。已知参与金葡菌黏附的主要分子有纤维结合素结合蛋白(FnBP)、凝集因子A (ClfA)、凝集因子B(ClfB)、胶原连接蛋白(Can)等。
本研究采用原核表达的FnBP和ClfA蛋白,纯化后制备亚单位疫苗,免疫小鼠进行疫苗评价。因为金葡菌是典型的胞外寄生菌,体液免疫对预防金葡菌感染起重要作用,IL-6的作用之一就是促进抗体的产生,本研究克隆表达出奶牛白细胞介素6(IL-6)作为亚单位疫苗的佐剂。用小鼠进行乳房炎疫苗效果评价,要先建立小鼠乳房炎模型,取泌乳8-10天的小鼠,第四对乳腺内注射不同剂量的金葡菌或PBS,2h后母子合笼,24h后处死母鼠,取乳腺进行一侧甲醛固定进行病理检测,另外一侧研磨检测组织中金葡菌的数量和TNF-α的浓度。用纯化的FnBP和C1fA蛋白加入氟氏不完全佐剂制备亚单位疫苗,培养金葡菌收菌后通过反复冻融超声破碎加入氟氏不完全佐剂制备全菌疫苗,间隔14天免疫小鼠两次,一部分使怀孕,泌乳后攻菌,另一部分加强免疫时注射不同的佐剂(PHA,LPS,IL-6,IFN-γ,胸腺肽),免疫不同时间点采血分离血清,用ELISA法检测血清中抗体水平。
结果成功克隆表达了奶牛IL-6基因,并纯化出蛋白；建立了金葡菌感染小鼠乳房炎模型,确定1.0×103cfu／只金葡菌是合适的乳腺内感染剂量,和评价小鼠乳房炎的严重程度三个有效指标。免疫结果显示,亚单位疫苗和全菌疫苗都可以减轻乳腺内感染金葡菌造成的乳房炎严重程度,表现为病理变化轻,组织中金葡菌数量少,TNF-α水平低。以全菌总蛋白为抗原,用琼扩试验检测血清中的抗体,只有全菌免疫组有可见的沉淀线,以纯化的两种蛋白包板,用ELISA检测血清中的抗体显示亚单位疫苗组的抗体水平最高。而5种不同种类的佐剂对血清中抗体的水平有不同的影响,其中以胸腺肽增加血清中抗体的作用最明显。
Bovine mastitis, one of the most significant disease of dairy herds, has huge effects on farm economics due to reduction in milk production and treatment costs. It's a multiple reasons disease, thus we must Application of a variety of measures to control bovine mastitis.As there are many kinds of Microorganism have a role in the processes of mastitis, the vaccine become a important target for control bovine mastitis.
Staphylococcus aureus (S. aureus) is the main causative agent of bovine mastitis, development an efficient vaccine of S.aureus is important for control the infection,there are several vaccines used in commercially herds, but the economic benefit following such treatment has not been uniformly demonstrated. With the development of biotechnology, new type vaccine emerged one after another, researchers also used these new technology for the vaccine 'invention. Followed the knowledge improve about the S.aureus infected in mammary gland, peoples found it's the key step of S.aureus adhesion to the host celles or extracelluar matrix. The adhesion molecules yet become the potential candidate antigens. As is know about the molecules include the Fibronectin binding protein (FnBP), clumping factor A (ClfA),clumping factor B(ClfB), Collagen-binding protein Can (Can) et al.
In this study, we choose prokaryotic express proteins of FnBP and ClfA, purificated for prepared the subunit vaccine. Evaluate the effectiveness on mouse model. S. aureus is a bacteria planted out of the host celles, Humoral immune palys an important role in resistancing S. aureus infection. As well know it have an important role to enhance the IgG level. That we clones the IL-6 gene of cows and expressed in prokaryotic express system. Using the IL-6 as an adjuvant for subunit vaccine. We established a mastitis mouse model before to evaluated the vaccine, take mice at 8-10days during lactating, injection different dose S. aureus or PBS into the fourth pair mammary glands,2 hours later take mother-children co-cage,24 hours apart after injection, killed mice by cervical pull, remove one side of mammary gland fixed for histopathologic evaluations, another side pulverization to detect the bacteria amount and the tumor necrosis factor (TNF-α) concentration. Through the mouse model we gained the suitable dose of S. aureus to challenge after vaccination. Take purificated proteins add adjuvant prepared subunit vaccine, and collection S. aureus lysis using Ultrasonic, add adjuvant to prepared total bacteria vaccine. Mice were vaccinated twice 14 days apart, one group cohabit to pregnancy, after parturition give S. aureus injection to challenge evaluation, another group give different adjuvant (PHA, LPS, IL-6, IFN, thymosin) with second vaccinated, haemospasia and apart serum every week, detect the IgG level in serum used the ELISA.
Results, we got purificated bovine IL-6, through clone and prokaryotic expression, established a mastitis mouse model, gained the suitable dose of S. aureus was 1.0×103cfu per mouse.and the scientific criteria to evaluated the severity of mouse mastitis. Both of the two vaccine can significantly reduce the severity of mastitis in mouse model, with a light histopathologic changes, lower TNF-αlevel and a small amount of bacteria in mammary gland tissues.The total protein vaccine group shown a highest total IgG level, but the subunit vaccine group shown a highest anti-FnBP & ClfA antibody, every adjuvant can enhance the IgG level rising significantly, the thymosin was the best one between the five adjuvants.
引文
[1]赵兴绪.兽医产科学[M].北京：中国农业出版社(第4版),2009：498-500.
[2]watts J.L. Etiological agents of bovine mastitis[J]. Veterinary Microbiology,1988, 16(1):41-66
[3]林锋强,潘杭君,胡松华.奶牛乳房炎疫苗研究进展.中国奶牛,2002,(1)：40-42
[4]刘文进,陈创夫,吴洁等.新疆垦区奶牛乳房炎致病菌的调查[J].黑龙江畜牧兽医,2005(10)：45-47
[5]王晓兰,孙庆华.奶牛隐性乳房炎病原菌的分离鉴定与药物敏感性试验[J].畜牧与兽医,2005,37(10)：43-44
[6]Kerro-Dego O., van Dijk J.E., Nederbragt H.,et al.Factors involved in the early pathogenesis of bovine Staphylococcus aureus mastitis with emphasis on bacterial adhesion and invasion[J]. A review. Vet. Quart.2002.24:181-198.
[7]Gresham H D, Lowrance J H, Caver T E, et al. Survival of Staphylococcus aureusinside neutrophils contributes to infection[J]. J Immunol,2000,64:3713--3722.
[8]Foster T J. Potential for vaccination against infections caused by Staphylococcus aureus[J]. Vaccine,1991,(9):221-227.
[9]Giraudo J A, Calzolari A,Rampone H,et al.Field trials of a vaccine against bovine mastitis.1. Evaluation in heifers[J]. J Dairy Sci,1997,80:845-853.
[10]Buzzola FR, Barbagelata MS, Caccuri RL,et al. Attenuation and persistence of and ability to induce protective immunity to a Staphylococcus aureus aroA mutant in mice[J]. Infect Immun.2006; 74(6):3498-3506.
[11]Pellegrino M, Giraudo J, Raspanti C,et al. Experimental trial in heifers vaccinated with Staphylococcus aureus avirulent mutant against bovine mastitis[J]. Vet Microbiol.2008,5;127(1-2):186-190.
[12]Nordhaug M L, Nesse L L, Norcross N L, et al. A field trial with an experimental vaccine against Staphylococcus aureus mastitis in cattle 1.Clinical parameters[J]. J.Dairy Sci,1994,77:1267-1275.
[13]Nordhaug M L,Nesse L L, Norcross N L, et al. A field trial with an experimental vaccine againstStaphylococcus aureusmastitis in cattle.2.Antibody response[J]. J Dairy Sci,1994,77:1276-1284.
[14]Nickerson S C, Owens W E, Boddie R L. Efficacy of a Staphylococcus mastitis vaccine in dairy heifers. Symposium on Immunology of Ruminant Mammary Gland [M]. Stress, Italy:Milan University Press,2000:246-251.
[15]Middleton JR, Ma J, Rinehart CL,et al. Efficacy of different Lysigin formulations in the prevention of Staphylococcus aureus intramammary infection in dairy heifers[J]. J Dairy Res.2006;73(l):10-19.
[16]Perez M.M., Prenafeta A., Valle J.,et al. Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl-β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria[J]. Vaccine2009,27:2379-2386
[17]Rather, P N, Davis A P,Wilkinson B J.Slime production by bovine milk Staphylococcus aureus and identification of coagulase-negative staphylococcal isolates[J]. J Clin Microbiol,1986,23:858-862
[18]Castagliuolo I.,Piccinini R.,Beggiao E.,et al. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice[J].vaccine,2006;24(20):4393-4402.
[19]Chang BS, Moon JS, Kang HM, et al. Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle[J]. Vaccine.2008 Apr 16;26(17):2081-2091.
[20]Grundmeier M,Hussain M,Becker P.Truncation of fibronectin-binding proteins in Staphylococcus aureusstrain newman leads to deficient adherence and host cell invasion due to loss of the cell wall anchor function[J].Infect Immun,2004, 72:7155-7163.
[21]Kerdudou S, Laschke M W, Sinha B, et al.Fibronectin binding proteins contribute to the adherence of Staphylococcus aureus to intact endotheliumin vivo[J]. Thromb Haemost,2006,96(2):183-189.
[22]Mamo W, Jonsson P, Flock J I, et al.Vaccination against Staphylococcus aureus mastitis:immunological response of mice vaccinated with fibronectin binding protein (FnBP-A) to challenge with S.aureus[J].Vaccine,1994,12(11):988-992.
[23]Rennermalm A,Li Y.H.,Bohaufs L.,et al. Antibodies against a truncated Staphy-lococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat [J]. Vaccine,2001,19(25-26):3376-3383.
[24]Jose P S, Daniela M R,Jaim S O,et al.Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach [J]. Vaccine,2003,21(20-21):2661
[25]Shkreta L, Talbot BG, Diarra MS,et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows.[J] Vaccine.2004;23(1):114-126.
[26]Brouillette, E., Lacasse, P., Shkreta, L.,et al. DNA immunization against the clumping factor A(ClfA) of Staphylococcu aureus[J].Vaccine 2002.20, 2348-2357.
[27]Nour El-Din,Adel N M.DNA immunization of dairy cows with the clumping factor A ofStaphylococcus aureus[J].Vaccine,2006,24(12):1997-2006.
[28]McAleese F.M., Walsh E.J., Sieprawska M,et al. Loss of Clumping Factor B Fibrinogen Binding Activity by Staphylococcus aureus Involves Cessation of Transcription,Shedding and Cleavage by Metalloprotease[J]. the journal of biological chemistry; 2001,276 (32):29969-29978.
[29]Espech M.C., Otero M.C., Sesma F.,et al. Screening of surface properties and antagonistic substances production by lactic acid bacteria isolated from the mammary gland of healthy and mastitic cows[J]. Veterinary Microbiology,2009, 135:346-357.
[30]胡佳杰,肖爱清,黄海浪等.重组耻垢分枝杆菌-Sj26 GST疫苗的免疫保护作用研究[J].疾病控制杂志,2003,7(3)：204-206.
[31]Cayabab M J, Hovav A H, Hsu T, et al. Generation of CD8+T cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env[J]. J.V i rol,2006,80(4): 1645-1652.
[32]Hansen G, Yeung VP, Berry G, et al. Vaccination with heat-killed L isteria as adjuvant reverses established allergen-induced airway hyperreactivity and inflammation:role of CD8+ T cells and L-18[J].Immunol 2000,164(1):223-230.
[33]Harrod T, Martin M, Russell M W.Long-term persistence and recall of immune responses in aged mice after mucosal immunization [J].Oral Microbiology & Immunology[J].2001,16 (3):170-177.
[34]Takahashi H, Sasaki K, Takahashi M. Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Thl responses of CD4+ and CD8+ T cells to nasal killed bacillus calmetteguerin in mice[J]. Vaccine,2006,24 (17):3591-3598.
[35]王冠,沈叙庄.黏膜传递系统和黏膜免疫佐剂研究进展[J].中华微生物学和免疫学杂志,2006,26(7)：672-674.
[36]Kauf AC, Vinyard BT, Bannerman DD. Effect of intramammary infusion of bacterial lipopolysaccharide on experimentally induced Staphylococcus aureus intramammary infection[J]. Res Vet Sci.2007 Feb;82(1):39-46.
[37]张小飞,杨倩.黏膜免疫佐剂的研究进展[J].免疫学杂志,2004,20(3)：62-65.
[38]Rose S. C., Oleg S. T., Arthur M. K..et al. CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity [J]. The Journal of Experimental Medicine,1997;186 (10):1623-1631
[39]Wang Y.,Shan C.,Jiang G.T.,et al. Immunoadjuvant effects of bacterial genomic DNA and CpG oligodeoxynucleotides on avian influenza virus subtype H5N1 inactivated oil emulsion vaccine in chicken[J]. Res Vet Sci.2009;86(3):399-405.
[40]Zhu Y, Fan H, Miao J,et al. Protective effect of CpG-DNA against mastitis induced by Escherichia coli infection in a rat model.[J]. Vet J.2008; 175(3): 369-378.
[41]Halperin SA, Van-Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine,2003, 21 (19-20):2461-2467.
[42]李忠明.当代新疫苗.北京：高等教育出版社,2001：93-101.
[43]周莲娣,张起辉,李建春.吴茱萸对小鼠肠道黏膜相关淋巴组织影响的实验研究[J].中国医药科学,2005,23(10)：1848-1849.
[44]周莲娣,郑丽,刘英杰等.香菇多糖对约氏疟原虫感染BALB/c小鼠Th1型应答的调节作用[J].人畜共患病学报.2008,24(4)：299-302.
[45]Markova N, Kussovski V, Drandarska I, et al. Protective activity of Lentinan in experimental tuberculosis[J]. Int Immunopharmacol,2003,3(10-11): 1557-1562.
[46]何萍.纳米铝佐剂的制备及其辅佐HBsAg免疫学效应研究.[D]重庆：第三军医大学,2004.
[47]Valliet R. Imp roved technique for the p reparation of water-in-oil emulsions containing p rotein antigens[J].B iotechniques 1996,20(5):797-800.
[48]Derek T. O'Hagan.Vaccine Adjuvants:Preparation Methods and Study Protocols[M]. New Jersey:HumanPress,2000.211-228.
[49]Podda A, Del Gudice G. MF59 adjuvanted vaccines:increased immunogenicity with an op timal safety p rofile[J]. Exper Rev Vaccines 2003,2 (2):197-203.
[50]Goto N. Local Tissue Irritating effects and adjuvant activities of Calcium phosphate and Aluminium Hydroxide with different physical properties [J]. Vaccine,1997,15:1364-1371.
[51]Morein B, Bengtsson K L. Immunomodulation by Iscoms Immune Stimulating Complexes[J].Methods,1999,19 (1):94-102.
[52]Goulter A, Harris R. Intranasal vaccination with ISCOMATRIX adjuvant influenza vaccine[J]. Vaccine 2003,21 (9-10):946-949.
[53]Derek T. O'Hagan.Vaccine Adjuvants:Preparation Methods and Study ProtocolsfM]. new jersey:Humana Press,2000:239-248
[54]Hu K, Chen M, Abusugra I, et al. Different Respiratory Syncytial Virus and Quillaja Saponin Formulations Induce Murine Peritoneal Cells to Express Different Proinflammatory Cytokine Profiles [J].FEMS Immunol Med M icrobiol,2001,31 (2):105-112.
[55]Nguyen T V, Iosef C, Jeong K, et al. Protection and Antibody Responses to Oral Priming by A ttenuated Human Rotavirus Followed by Oral Boosting with 2/6-rotavirus-like Particles with Immunostimulating Complexes in Gnotobiotic Pigs[J]. Vaccine,2003,21 (25-26):4059-4070.
[56]Liu GL, Wang JQ, Bu DP, Cheng JB,et al. Specific immune milk production of cows implanted with antigen-release devices[J].J Dairy Sci.2009;92(1):100-108.
[57]Brouillete E, Malouin F. The pathogenesis and control of Staphylococcus aureus induced mastitis study model in the mouse[J]. Microb Infect,2005,7(3): 560-568.
[58]Chandler R L. Experimental bacterial mastitis in the mouse[J]. J Med Microbial,1970,3(2):273-282.
[59]朱于敏,苗晋锋,邹思湘等CpG-DNA对金黄色葡萄球菌诱导的乳腺炎大鼠的保护研究[J].中国农业科学2007,40(1)：183-189
[60]叶宝娜,王林国,郝满良等.金黄色葡萄球菌诱发小鼠试验性乳腺炎模型的建立[J].中国乳业2008,(1)：62-64
[61]钟凯,王艳玲,刘仪等.内毒素诱发睢宁白山羊实验性乳腺炎模型的建立及黄芪多糖对其的影响[J].中国兽医学报,2008,28(7)：844-847.
[62]Eric Brouillette, Gilles Grondin, Celine Lefebvre,et al. Mouse mastitis model of infection for antimicrobial compound efficacy studies against intracellular and extracellular forms of Staphylococcus aureus[J].Veterinary Microbiology2004, 101:253-262
[63]Beibei Gu, Yumin Zhu, Wei Zhu,et al. Retinoid protects rats against neutrophil-induced oxidative stress in acute experimental mastitis[J] International Immunopharrmacology,2009,(9):223-229
[1]赵兴绪.兽医产科学[M].北京：中国农业出版社(第4版)2009：498.
[2]Medunitsin N V, Avdeeva J I, Acolzina S E, et al.Presence of cytokines in biological preparations [J]. Biologicals,2002,30(1):1-6.
[3]Kabaroff L, Boermans H, Karrow N A. Changes in ovine maternal temperature, and serum cortisol and interleukin-6 concentrations after challenge with Escherichia coli lipopolysaccharide during pregnancy and early lactation [J]. Journal of Animal Science,2006,84(8):2083-2088.
[4]周光炎.免疫学原理[M].上海：上海科学技术出版社,2007：324.
[5]Muraguchi A,Hirano T,Tang B,et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells[J]. Journal of Experimental Medicine.1988,167:332-344.
[6]Castell J V, Gomez-Lechon M J, David M, et al. Acute-phase response of human hepatocytes:regulation of acute-phase protein synthesis by interleukin-6[J]. Hepatology,1990,12(5):1179-1186.
[7]萨姆布鲁克J,拉赛尔D W.分子克隆实验指南[M].黄培堂.北京：科学出版社,2002.
[8]Xia C,Dan W,Wen-Xue W,et al.Cloning and expression of interferon-alpha/gamma from a domestic porcine breed and its effect on classical swine fever virus[J]. Veterinary Immunology and Immunopathology,2005,104(l-2):81-89.
[9]Riehard PN,Janet GP,Stuart R. Purification and NH2-terminal sequence of a plasmcytoma groth factor derived from the murine macrophage cell line P388[J]. The Joural of Immunology,1987,139:813-817.
[10]严琳,何盖启,陈焕春等.基因缺失疫苗的佐剂效应研究[J].中国农业科学.2003,36(10)：1213-1215.
[11]孟庆玲,乔军,才学鹏.中国白兔IL-6基因的分子克隆及其表达研究[J].西南师范大学学报(自然科学版),2007,32(5),74-78.
[12]孙强明RhuGM-CSF/IL-6融合蛋白基因的构建、表达及生物学活性研究[博士学位论文].北京：中国协和医科大学,2002.5.
[13]Houssiau FA,Coulie PG.,Olive D,et al.Synergistic activation of human T cells by interleukin 1 and interleukin 6[J].Eur.J.Immunol.1988,18,653-656.
[1]Sutra L,Poutrel B.Virulence factors involved in the pathogenesis of bovine intramammary infections due to Staphylococcus aureus[J]. J Med Microbial, 1994,40 (2):79-89.
[2]Sanchez M S, Chandler R L. Experimental bacterial mastitis in the mouse[J]. J Med Microbial,1970,3(2):273-282.
[3]朱于敏,苗晋锋,邹思湘等.CpG-DNA对金黄色葡萄球菌诱导的乳腺炎大鼠的保护研究[J].中国农业科学2007,40(1)：183-189
[4]叶宝娜,王林国,郝满良等.金黄色葡萄球菌诱发小鼠试验性乳腺炎模型的建立[J].中国乳业,2008,(1)：62-64
[5]伦艳霞,王娜娜,王家鑫.BALB/c小鼠无乳链球菌性乳腺炎模型的建立[J].中国奶牛2008,(1)：35-38
[6]Brouillete E,Malouin F. The pathogenesis and control of Staphylococcus aureus induced mastitis study model in the mouse[J]. Microb Infect,2005,7(3):560-568.
[7]Rambeaud M, Almeida R A, Pighetti G M, et al.Dynamics of leukocytes and cytokines during experimentally induced Streptococcus uberis mastitis[J]. Veterinary Immunology and Immunopathology,2003,96(3-4):193-205.
[8]Winter P, Colditz L G. Immunological response of the lactating bvine udder following experimental challenge with Staphylococcus epidermidis[J]. Veterinary Immunology and Immunopathology,2002,89(1-2):57-65.
[9]周光炎.免疫学原理[M].上海：上海科技出版社,2007：134.
[10]孔祥复,黄建东.小鼠模型与人类疾病[J].中国医学科学院学报,2001,23(1)：2-7.
[11]邱昌庆,周继章,程淑敏等.乳牛衣原体病灭活疫苗效检小鼠模型的建立[J].中国兽医科学,2008,38(02)：120-122.
[1]Kerro-Dego, O. van,Dijk, J.E., Nederbragt, H.. Factors involved in the early pathogenesis of bovine Staphylococcus aureus mastitis with emphasis on bacterial adhesion and invasion. A review. Vet. Quart.2002,24,181-198.
[2]Leitner G, Yadlin N, Lubashevsy E,et al.Development of a Staphylococcus aureus vaccine against mastitis in dairy cows[J]. Vet Immunol Immunopathol. 2003;93(3-4):153-158.
[3]Shkreta L, Talbot BG, Diarra MS,et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows.[J] Vaccine.2004;23(1):114-126.
[4]Castagliuolo I, Piccinini R, Beggiao E,et al.Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice[J] Vaccine.2006;24(20):4393-4402.
[5]赵艳,张爱荣.奶牛乳房炎金黄色葡萄球菌黏附素疫苗的研究进展[J].畜牧与饲料科学,2008,(3)：82-85.
[6]傅林锋,常娅莉,裴明玉等.鼠疫溶菌疫苗免疫小鼠的体液免疫应答[J].微生物学免疫学进展.2008.36(4).16-24.
[7]何昭阳,胡桂学,王春凤.动物免疫学试验技术[M].长春：吉林科学技术出版社,2002.
[8]Grundmeier M,Hussain M,Becker P.Truncation of fibronectin-binding proteins in Staphylococcus aureusstrain newman leads to deficient adherence and host cell invasion due to loss of the cell wall anchor function[J]. Infect Immun,2004, 72:7155-7163.
[9]Kerdudou S, Laschke M W, Sinha B, et al.Fibronectin binding proteins contribute to the adherence of Staphylococcus aureus to intact endotheliumin vivo[J]. Thromb Haemost,2006,96(2):183-189.
[10]Mamo W, Jonsson P, Flock J I, et al.Vaccination against Staphylococcus aureus mastitis:immunological response of mice vaccinated with fibronectin binding protein (FnBP-A) to challenge with S.aureus[J].Vaccine,1994,12(11):988-992.
[11]Rennermalm A,Li Y.H.,Bohaufs L.,et al. Antibodies against a truncated Staphy-lococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat [J]. Vaccine,2001,19(25-26):3376-3383.
[12]Jose P S, Daniela M R,Jaim S O,et al.Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach [J]. Vaccine,2003,21(20-21):2661
[13]Shkreta L, Talbot BG, Diarra MS,et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows.[J] Vaccine.2004;23(1):114-126.
[14]Nour El-Din,Adel N M.DNA immunization of dairy cows with the clumping factor A ofStaphylococcus aureus[J].Vaccine,2006,24(12):1997-2006.
[15]Castagliuolo I.,Piccinini R.,Beggiao E.,et al. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice[J].vaccine,2006;24(20):4393-4402.
[16]Rambeaud M, Almeida R A, Pighetti G M, et al.Dynamics of leukocytes and cytokines during experimentally induced Streptococcus uberis mastitis[J]. Veterinary Immunology and Immunopathology,2003,96(3-4):193-205.
[17]赵德明.兽医病理学[M].北京：中国农业出版社,1998：103-109
[18]刘君.牛源金黄色葡萄球菌黏附因子FnBP和clfA的克隆与原核表达[硕士学位论文].新疆石河子：石河子大学,2008
[19]郭爽,索江华,苏丽娟.植物血凝素对小白鼠免疫功能的影响[J].安徽农业科学,2007,35(34)：11117-11118
[20]莫菲,许巧丽,张军忍等.植物血凝素对鸡免疫功能的影响[J]甘肃农业大学学报,2009,44(1)：36-40
[21]秦福丽,张绍林,孙慧等.植物血凝素对杀伤细胞增殖和细胞毒作用影响的研究[J]临床血液学杂志,2004,17(6)：340-342
[22]李传友,刘忠泉,李卫民等.脂多糖对感染卡介苗巨噬细胞表达细胞因子影响的研究[J].中国防痨杂志,2004,26(3)：133-136.
[23]林兰,刘建文.胸腺肽制剂及临床应用研究现状[J].中国药事,2009,23(7)：706710
[24]周光炎.免疫学原理[M].上海：上海科学技术出版社,2007：87
[2]watts J.L. Etiological agents of bovine mastitis[J]. Veterinary Microbiology,1988, 16(1):41-66
[3]林锋强,潘杭君,胡松华.奶牛乳房炎疫苗研究进展.中国奶牛,2002,(1)：40-42
[4]刘文进,陈创夫,吴洁等.新疆垦区奶牛乳房炎致病菌的调查[J].黑龙江畜牧兽医,2005(10)：45-47
[5]王晓兰,孙庆华.奶牛隐性乳房炎病原菌的分离鉴定与药物敏感性试验[J].畜牧与兽医,2005,37(10)：43-44
[6]Kerro-Dego O., van Dijk J.E., Nederbragt H.,et al.Factors involved in the early pathogenesis of bovine Staphylococcus aureus mastitis with emphasis on bacterial adhesion and invasion[J]. A review. Vet. Quart.2002.24:181-198.
[7]Gresham H D, Lowrance J H, Caver T E, et al. Survival of Staphylococcus aureusinside neutrophils contributes to infection[J]. J Immunol,2000,64:3713--3722.
[8]Foster T J. Potential for vaccination against infections caused by Staphylococcus aureus[J]. Vaccine,1991,(9):221-227.
[9]Giraudo J A, Calzolari A,Rampone H,et al.Field trials of a vaccine against bovine mastitis.1. Evaluation in heifers[J]. J Dairy Sci,1997,80:845-853.
[10]Buzzola FR, Barbagelata MS, Caccuri RL,et al. Attenuation and persistence of and ability to induce protective immunity to a Staphylococcus aureus aroA mutant in mice[J]. Infect Immun.2006; 74(6):3498-3506.
[11]Pellegrino M, Giraudo J, Raspanti C,et al. Experimental trial in heifers vaccinated with Staphylococcus aureus avirulent mutant against bovine mastitis[J]. Vet Microbiol.2008,5;127(1-2):186-190.
[12]Nordhaug M L, Nesse L L, Norcross N L, et al. A field trial with an experimental vaccine against Staphylococcus aureus mastitis in cattle 1.Clinical parameters[J]. J.Dairy Sci,1994,77:1267-1275.
[13]Nordhaug M L,Nesse L L, Norcross N L, et al. A field trial with an experimental vaccine againstStaphylococcus aureusmastitis in cattle.2.Antibody response[J]. J Dairy Sci,1994,77:1276-1284.
[14]Nickerson S C, Owens W E, Boddie R L. Efficacy of a Staphylococcus mastitis vaccine in dairy heifers. Symposium on Immunology of Ruminant Mammary Gland [M]. Stress, Italy:Milan University Press,2000:246-251.
[15]Middleton JR, Ma J, Rinehart CL,et al. Efficacy of different Lysigin formulations in the prevention of Staphylococcus aureus intramammary infection in dairy heifers[J]. J Dairy Res.2006;73(l):10-19.
[16]Perez M.M., Prenafeta A., Valle J.,et al. Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl-β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria[J]. Vaccine2009,27:2379-2386
[17]Rather, P N, Davis A P,Wilkinson B J.Slime production by bovine milk Staphylococcus aureus and identification of coagulase-negative staphylococcal isolates[J]. J Clin Microbiol,1986,23:858-862
[18]Castagliuolo I.,Piccinini R.,Beggiao E.,et al. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice[J].vaccine,2006;24(20):4393-4402.
[19]Chang BS, Moon JS, Kang HM, et al. Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle[J]. Vaccine.2008 Apr 16;26(17):2081-2091.
[20]Grundmeier M,Hussain M,Becker P.Truncation of fibronectin-binding proteins in Staphylococcus aureusstrain newman leads to deficient adherence and host cell invasion due to loss of the cell wall anchor function[J].Infect Immun,2004, 72:7155-7163.
[21]Kerdudou S, Laschke M W, Sinha B, et al.Fibronectin binding proteins contribute to the adherence of Staphylococcus aureus to intact endotheliumin vivo[J]. Thromb Haemost,2006,96(2):183-189.
[22]Mamo W, Jonsson P, Flock J I, et al.Vaccination against Staphylococcus aureus mastitis:immunological response of mice vaccinated with fibronectin binding protein (FnBP-A) to challenge with S.aureus[J].Vaccine,1994,12(11):988-992.
[23]Rennermalm A,Li Y.H.,Bohaufs L.,et al. Antibodies against a truncated Staphy-lococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat [J]. Vaccine,2001,19(25-26):3376-3383.
[24]Jose P S, Daniela M R,Jaim S O,et al.Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach [J]. Vaccine,2003,21(20-21):2661
[25]Shkreta L, Talbot BG, Diarra MS,et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows.[J] Vaccine.2004;23(1):114-126.
[26]Brouillette, E., Lacasse, P., Shkreta, L.,et al. DNA immunization against the clumping factor A(ClfA) of Staphylococcu aureus[J].Vaccine 2002.20, 2348-2357.
[27]Nour El-Din,Adel N M.DNA immunization of dairy cows with the clumping factor A ofStaphylococcus aureus[J].Vaccine,2006,24(12):1997-2006.
[28]McAleese F.M., Walsh E.J., Sieprawska M,et al. Loss of Clumping Factor B Fibrinogen Binding Activity by Staphylococcus aureus Involves Cessation of Transcription,Shedding and Cleavage by Metalloprotease[J]. the journal of biological chemistry; 2001,276 (32):29969-29978.
[29]Espech M.C., Otero M.C., Sesma F.,et al. Screening of surface properties and antagonistic substances production by lactic acid bacteria isolated from the mammary gland of healthy and mastitic cows[J]. Veterinary Microbiology,2009, 135:346-357.
[30]胡佳杰,肖爱清,黄海浪等.重组耻垢分枝杆菌-Sj26 GST疫苗的免疫保护作用研究[J].疾病控制杂志,2003,7(3)：204-206.
[31]Cayabab M J, Hovav A H, Hsu T, et al. Generation of CD8+T cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env[J]. J.V i rol,2006,80(4): 1645-1652.
[32]Hansen G, Yeung VP, Berry G, et al. Vaccination with heat-killed L isteria as adjuvant reverses established allergen-induced airway hyperreactivity and inflammation:role of CD8+ T cells and L-18[J].Immunol 2000,164(1):223-230.
[33]Harrod T, Martin M, Russell M W.Long-term persistence and recall of immune responses in aged mice after mucosal immunization [J].Oral Microbiology & Immunology[J].2001,16 (3):170-177.
[34]Takahashi H, Sasaki K, Takahashi M. Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Thl responses of CD4+ and CD8+ T cells to nasal killed bacillus calmetteguerin in mice[J]. Vaccine,2006,24 (17):3591-3598.
[35]王冠,沈叙庄.黏膜传递系统和黏膜免疫佐剂研究进展[J].中华微生物学和免疫学杂志,2006,26(7)：672-674.
[36]Kauf AC, Vinyard BT, Bannerman DD. Effect of intramammary infusion of bacterial lipopolysaccharide on experimentally induced Staphylococcus aureus intramammary infection[J]. Res Vet Sci.2007 Feb;82(1):39-46.
[37]张小飞,杨倩.黏膜免疫佐剂的研究进展[J].免疫学杂志,2004,20(3)：62-65.
[38]Rose S. C., Oleg S. T., Arthur M. K..et al. CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity [J]. The Journal of Experimental Medicine,1997;186 (10):1623-1631
[39]Wang Y.,Shan C.,Jiang G.T.,et al. Immunoadjuvant effects of bacterial genomic DNA and CpG oligodeoxynucleotides on avian influenza virus subtype H5N1 inactivated oil emulsion vaccine in chicken[J]. Res Vet Sci.2009;86(3):399-405.
[40]Zhu Y, Fan H, Miao J,et al. Protective effect of CpG-DNA against mastitis induced by Escherichia coli infection in a rat model.[J]. Vet J.2008; 175(3): 369-378.
[41]Halperin SA, Van-Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine,2003, 21 (19-20):2461-2467.
[42]李忠明.当代新疫苗.北京：高等教育出版社,2001：93-101.
[43]周莲娣,张起辉,李建春.吴茱萸对小鼠肠道黏膜相关淋巴组织影响的实验研究[J].中国医药科学,2005,23(10)：1848-1849.
[44]周莲娣,郑丽,刘英杰等.香菇多糖对约氏疟原虫感染BALB/c小鼠Th1型应答的调节作用[J].人畜共患病学报.2008,24(4)：299-302.
[45]Markova N, Kussovski V, Drandarska I, et al. Protective activity of Lentinan in experimental tuberculosis[J]. Int Immunopharmacol,2003,3(10-11): 1557-1562.
[46]何萍.纳米铝佐剂的制备及其辅佐HBsAg免疫学效应研究.[D]重庆：第三军医大学,2004.
[47]Valliet R. Imp roved technique for the p reparation of water-in-oil emulsions containing p rotein antigens[J].B iotechniques 1996,20(5):797-800.
[48]Derek T. O'Hagan.Vaccine Adjuvants:Preparation Methods and Study Protocols[M]. New Jersey:HumanPress,2000.211-228.
[49]Podda A, Del Gudice G. MF59 adjuvanted vaccines:increased immunogenicity with an op timal safety p rofile[J]. Exper Rev Vaccines 2003,2 (2):197-203.
[50]Goto N. Local Tissue Irritating effects and adjuvant activities of Calcium phosphate and Aluminium Hydroxide with different physical properties [J]. Vaccine,1997,15:1364-1371.
[51]Morein B, Bengtsson K L. Immunomodulation by Iscoms Immune Stimulating Complexes[J].Methods,1999,19 (1):94-102.
[52]Goulter A, Harris R. Intranasal vaccination with ISCOMATRIX adjuvant influenza vaccine[J]. Vaccine 2003,21 (9-10):946-949.
[53]Derek T. O'Hagan.Vaccine Adjuvants:Preparation Methods and Study ProtocolsfM]. new jersey:Humana Press,2000:239-248
[54]Hu K, Chen M, Abusugra I, et al. Different Respiratory Syncytial Virus and Quillaja Saponin Formulations Induce Murine Peritoneal Cells to Express Different Proinflammatory Cytokine Profiles [J].FEMS Immunol Med M icrobiol,2001,31 (2):105-112.
[55]Nguyen T V, Iosef C, Jeong K, et al. Protection and Antibody Responses to Oral Priming by A ttenuated Human Rotavirus Followed by Oral Boosting with 2/6-rotavirus-like Particles with Immunostimulating Complexes in Gnotobiotic Pigs[J]. Vaccine,2003,21 (25-26):4059-4070.
[56]Liu GL, Wang JQ, Bu DP, Cheng JB,et al. Specific immune milk production of cows implanted with antigen-release devices[J].J Dairy Sci.2009;92(1):100-108.
[57]Brouillete E, Malouin F. The pathogenesis and control of Staphylococcus aureus induced mastitis study model in the mouse[J]. Microb Infect,2005,7(3): 560-568.
[58]Chandler R L. Experimental bacterial mastitis in the mouse[J]. J Med Microbial,1970,3(2):273-282.
[59]朱于敏,苗晋锋,邹思湘等CpG-DNA对金黄色葡萄球菌诱导的乳腺炎大鼠的保护研究[J].中国农业科学2007,40(1)：183-189
[60]叶宝娜,王林国,郝满良等.金黄色葡萄球菌诱发小鼠试验性乳腺炎模型的建立[J].中国乳业2008,(1)：62-64
[61]钟凯,王艳玲,刘仪等.内毒素诱发睢宁白山羊实验性乳腺炎模型的建立及黄芪多糖对其的影响[J].中国兽医学报,2008,28(7)：844-847.
[62]Eric Brouillette, Gilles Grondin, Celine Lefebvre,et al. Mouse mastitis model of infection for antimicrobial compound efficacy studies against intracellular and extracellular forms of Staphylococcus aureus[J].Veterinary Microbiology2004, 101:253-262
[63]Beibei Gu, Yumin Zhu, Wei Zhu,et al. Retinoid protects rats against neutrophil-induced oxidative stress in acute experimental mastitis[J] International Immunopharrmacology,2009,(9):223-229
[1]赵兴绪.兽医产科学[M].北京：中国农业出版社(第4版)2009：498.
[2]Medunitsin N V, Avdeeva J I, Acolzina S E, et al.Presence of cytokines in biological preparations [J]. Biologicals,2002,30(1):1-6.
[3]Kabaroff L, Boermans H, Karrow N A. Changes in ovine maternal temperature, and serum cortisol and interleukin-6 concentrations after challenge with Escherichia coli lipopolysaccharide during pregnancy and early lactation [J]. Journal of Animal Science,2006,84(8):2083-2088.
[4]周光炎.免疫学原理[M].上海：上海科学技术出版社,2007：324.
[5]Muraguchi A,Hirano T,Tang B,et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells[J]. Journal of Experimental Medicine.1988,167:332-344.
[6]Castell J V, Gomez-Lechon M J, David M, et al. Acute-phase response of human hepatocytes:regulation of acute-phase protein synthesis by interleukin-6[J]. Hepatology,1990,12(5):1179-1186.
[7]萨姆布鲁克J,拉赛尔D W.分子克隆实验指南[M].黄培堂.北京：科学出版社,2002.
[8]Xia C,Dan W,Wen-Xue W,et al.Cloning and expression of interferon-alpha/gamma from a domestic porcine breed and its effect on classical swine fever virus[J]. Veterinary Immunology and Immunopathology,2005,104(l-2):81-89.
[9]Riehard PN,Janet GP,Stuart R. Purification and NH2-terminal sequence of a plasmcytoma groth factor derived from the murine macrophage cell line P388[J]. The Joural of Immunology,1987,139:813-817.
[10]严琳,何盖启,陈焕春等.基因缺失疫苗的佐剂效应研究[J].中国农业科学.2003,36(10)：1213-1215.
[11]孟庆玲,乔军,才学鹏.中国白兔IL-6基因的分子克隆及其表达研究[J].西南师范大学学报(自然科学版),2007,32(5),74-78.
[12]孙强明RhuGM-CSF/IL-6融合蛋白基因的构建、表达及生物学活性研究[博士学位论文].北京：中国协和医科大学,2002.5.
[13]Houssiau FA,Coulie PG.,Olive D,et al.Synergistic activation of human T cells by interleukin 1 and interleukin 6[J].Eur.J.Immunol.1988,18,653-656.
[1]Sutra L,Poutrel B.Virulence factors involved in the pathogenesis of bovine intramammary infections due to Staphylococcus aureus[J]. J Med Microbial, 1994,40 (2):79-89.
[2]Sanchez M S, Chandler R L. Experimental bacterial mastitis in the mouse[J]. J Med Microbial,1970,3(2):273-282.
[3]朱于敏,苗晋锋,邹思湘等.CpG-DNA对金黄色葡萄球菌诱导的乳腺炎大鼠的保护研究[J].中国农业科学2007,40(1)：183-189
[4]叶宝娜,王林国,郝满良等.金黄色葡萄球菌诱发小鼠试验性乳腺炎模型的建立[J].中国乳业,2008,(1)：62-64
[5]伦艳霞,王娜娜,王家鑫.BALB/c小鼠无乳链球菌性乳腺炎模型的建立[J].中国奶牛2008,(1)：35-38
[6]Brouillete E,Malouin F. The pathogenesis and control of Staphylococcus aureus induced mastitis study model in the mouse[J]. Microb Infect,2005,7(3):560-568.
[7]Rambeaud M, Almeida R A, Pighetti G M, et al.Dynamics of leukocytes and cytokines during experimentally induced Streptococcus uberis mastitis[J]. Veterinary Immunology and Immunopathology,2003,96(3-4):193-205.
[8]Winter P, Colditz L G. Immunological response of the lactating bvine udder following experimental challenge with Staphylococcus epidermidis[J]. Veterinary Immunology and Immunopathology,2002,89(1-2):57-65.
[9]周光炎.免疫学原理[M].上海：上海科技出版社,2007：134.
[10]孔祥复,黄建东.小鼠模型与人类疾病[J].中国医学科学院学报,2001,23(1)：2-7.
[11]邱昌庆,周继章,程淑敏等.乳牛衣原体病灭活疫苗效检小鼠模型的建立[J].中国兽医科学,2008,38(02)：120-122.
[1]Kerro-Dego, O. van,Dijk, J.E., Nederbragt, H.. Factors involved in the early pathogenesis of bovine Staphylococcus aureus mastitis with emphasis on bacterial adhesion and invasion. A review. Vet. Quart.2002,24,181-198.
[2]Leitner G, Yadlin N, Lubashevsy E,et al.Development of a Staphylococcus aureus vaccine against mastitis in dairy cows[J]. Vet Immunol Immunopathol. 2003;93(3-4):153-158.
[3]Shkreta L, Talbot BG, Diarra MS,et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows.[J] Vaccine.2004;23(1):114-126.
[4]Castagliuolo I, Piccinini R, Beggiao E,et al.Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice[J] Vaccine.2006;24(20):4393-4402.
[5]赵艳,张爱荣.奶牛乳房炎金黄色葡萄球菌黏附素疫苗的研究进展[J].畜牧与饲料科学,2008,(3)：82-85.
[6]傅林锋,常娅莉,裴明玉等.鼠疫溶菌疫苗免疫小鼠的体液免疫应答[J].微生物学免疫学进展.2008.36(4).16-24.
[7]何昭阳,胡桂学,王春凤.动物免疫学试验技术[M].长春：吉林科学技术出版社,2002.
[8]Grundmeier M,Hussain M,Becker P.Truncation of fibronectin-binding proteins in Staphylococcus aureusstrain newman leads to deficient adherence and host cell invasion due to loss of the cell wall anchor function[J]. Infect Immun,2004, 72:7155-7163.
[9]Kerdudou S, Laschke M W, Sinha B, et al.Fibronectin binding proteins contribute to the adherence of Staphylococcus aureus to intact endotheliumin vivo[J]. Thromb Haemost,2006,96(2):183-189.
[10]Mamo W, Jonsson P, Flock J I, et al.Vaccination against Staphylococcus aureus mastitis:immunological response of mice vaccinated with fibronectin binding protein (FnBP-A) to challenge with S.aureus[J].Vaccine,1994,12(11):988-992.
[11]Rennermalm A,Li Y.H.,Bohaufs L.,et al. Antibodies against a truncated Staphy-lococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat [J]. Vaccine,2001,19(25-26):3376-3383.
[12]Jose P S, Daniela M R,Jaim S O,et al.Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach [J]. Vaccine,2003,21(20-21):2661
[13]Shkreta L, Talbot BG, Diarra MS,et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows.[J] Vaccine.2004;23(1):114-126.
[14]Nour El-Din,Adel N M.DNA immunization of dairy cows with the clumping factor A ofStaphylococcus aureus[J].Vaccine,2006,24(12):1997-2006.
[15]Castagliuolo I.,Piccinini R.,Beggiao E.,et al. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice[J].vaccine,2006;24(20):4393-4402.
[16]Rambeaud M, Almeida R A, Pighetti G M, et al.Dynamics of leukocytes and cytokines during experimentally induced Streptococcus uberis mastitis[J]. Veterinary Immunology and Immunopathology,2003,96(3-4):193-205.
[17]赵德明.兽医病理学[M].北京：中国农业出版社,1998：103-109
[18]刘君.牛源金黄色葡萄球菌黏附因子FnBP和clfA的克隆与原核表达[硕士学位论文].新疆石河子：石河子大学,2008
[19]郭爽,索江华,苏丽娟.植物血凝素对小白鼠免疫功能的影响[J].安徽农业科学,2007,35(34)：11117-11118
[20]莫菲,许巧丽,张军忍等.植物血凝素对鸡免疫功能的影响[J]甘肃农业大学学报,2009,44(1)：36-40
[21]秦福丽,张绍林,孙慧等.植物血凝素对杀伤细胞增殖和细胞毒作用影响的研究[J]临床血液学杂志,2004,17(6)：340-342
[22]李传友,刘忠泉,李卫民等.脂多糖对感染卡介苗巨噬细胞表达细胞因子影响的研究[J].中国防痨杂志,2004,26(3)：133-136.
[23]林兰,刘建文.胸腺肽制剂及临床应用研究现状[J].中国药事,2009,23(7)：706710
[24]周光炎.免疫学原理[M].上海：上海科学技术出版社,2007：87